Refine by
Pancreatic Articles & Analysis: Older
140 news found
” Ace Therapeutics’ mouse models mimic the key characteristics of human diabetes, such as hyperglycemia, insulin resistance, and pancreatic dysfunction, making them invaluable for investigating disease pathology and testing new therapeutics. ...
Key features of Ace Therapeutics' disease model customization services include the ability to customize esophageal disease models, gastrointestinal disease models, liver disease models, pancreatic disease models, and more. Additionally, researchers can benefit from comprehensive data analysis and validation services to ensure the reliability and reproducibility of study results. ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. ...
About Chronic Kidney Disease in Type 1 Diabetes T1D is a chronic autoimmune disorder characterized by destruction of pancreatic beta cells leading to insulin deficiency and requiring lifelong insulin treatment. ...
ByBayer AG
While the Company’s current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has plans to expand into other hard to detect and treat cancers such as brain, ovarian and pancreatic. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/. ...
Creative Enzymes is a leading biotechnology company supporting the development of diagnostic enzymes for kidney and pancreatic diseases. Pancreatitis is inflammation of the pancreatic tissue, which can be either acute or chronic. Pancreatic enzymes, including amylase, lipase, and trypsin, can be used to monitor the relative ...
Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ovarian, gastric, prostate, pancreatic, liver, and kidney cancers. He also discusses several of the company’s near-term pipeline products and other areas of possible development for the ...
While the Company current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has plan to expand into other hard to detect and treat cancers such as brain, ovarian and pancreatic. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the biotechnology industry, expanded its monoclonal antibodies capabilities and offerings to global customers, including over 1,000 of targets, carrier-free formulations, and conjugated antibodies. Monoclonal antibodies (mAbs) are generated by identical B cells that are cloned from a single parent cell. ...
Its first potential indication is pancreatic cancer, a particularly lethal disease that affects more than 53,000 Americans annually, where excruciating symptoms arise from the primary mass invading nearby vital organs. ...
In addition to the above studies, it is currently being evaluated in prostate cancer with further potential in pancreatic, ovarian and colorectal cancers. Samuraciclib has been granted Fast Track designations from the U.S. ...
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, ...
ByxCures
” Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development — all at a scale unmatched by ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
While the Company current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has plan to expand into other hard to detect and treat cancers such as brain, ovarian and pancreatic. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/. ...
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
COMPETE (NCT03049189) and COMPOSE (NCT04919226) are international, prospective, randomized, controlled, open-label, multi-center phase III clinical studies to evaluate the efficacy and safety, of ITM-11 compared to standard therapy in patients with inoperable, progressive, grade 1 and 2 (COMPETE) and aggressive grade 2 and 3 (COMPOSE), somatostatin receptor-positive (SSTR+) neuroendocrine tumors ...
While the Company current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has plan to expand into other hard to detect and treat cancers such as brain, ovarian and pancreatic. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/. ...
The Company maintains a pipeline of TCR therapies under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. More information is ...
Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem ...